Menu
Not yet recruiting NCT07584772

Use of D-Chiro-inositol in Male Functional Hypogonadism Associated With Sexual Dysfunction

No phase Interventional Functional Hypogonadism

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: D-chiro-inositol.
Who it may be relevant to
Registry conditions: Functional Hypogonadism. Basic parameters: 50 years — 75 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

A prospective, uncontrolled, non-pharmacological interventional study conducted on men with functional or borderline hypogonadism, aimed at evaluating, after 3 months of supplementation with D-Chiro-inositol, changes in hormonal profile and sexual function.

Detailed description

The study involves the recruitment of 35 functional hypogonadal patients aged between 50 and 75 years to the Andrology Unit of the "Antonio Cardarelli" Hospital. At T0 patients will undergo hematochemical evaluation of the following parameters: total and free testosterone, PSA and hematocrit.

At the same time, they will be provided with a self-assessment questionnaire on physical and sexual functioning. The same evaluations will be performed after 3 months of supplementation (T1).

The main endpoint is the intra-subject variation in total and free testosterone levels between T0 and T1.

Interventions

  • Dietary supplement D-chiro-inositol
    Treatment with D-chiro-inositol (capsule) for 3 months 600 mg/2 die

Primary outcome measures

  • Testosterone levels [Time frame: From enrollment to three months]

Eligibility criteria

Inclusion criteria

  • Men aged between 50 and 75
  • Affected by functional hypogonadism associated with male aging

Exclusion criteria

  • Elevated ferritin, PRL, and/or elevated CRP values; diagnosis of primary hypogonadism; diagnosis of organic hypogonadotropic hypogonadism or secondary to other ongoing acute or chronic pathologies; presence of other pituitary deficits.
  • Alcohol use and/or drug abuse, recent hormone treatment, smoking, systemic or endocrine diseases, infection of the male accessory glands, medical history of cryptorchidism or varicocele, and micro-orchidism.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07584772 · 07/26

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗